| 1028486-06-7

• 物质功能分类: 生物化工 - 抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• CAS: 1028486-06-7
• 化学式: C27H20ClFN4NaO4
• 分子量: 541.9
• InChiKey: UDTGEKCUEBGDEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.37
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• [EN] CRYSTALLINE FORMS OF SODIUM 4-{[9-CHLORO-7-(2-FLUORO-6--METHOXYPHENYL)-5H -PYRIMIDO[5,4-D][2]BENZAZEPIN-2YL]AMINO}-2-METHOXYBENZOATE<br/>[FR] FORMES CRISTALLINES DE 4-{[9-CHLORO-7-(2-FLUORO-6--MÉTHOXYPHÉNYL)-5H-PYRIMIDO[5,4-D][2]BENZAZÉPIN-2YL]AMINO}-2-MÉTHOXYBENZOATE DE SODIUM
  申请人：MILLENNIUM PHARM INC

  公开号：WO2011103089A1

  公开（公告）日：2011-08-25

  The present invention is directed to a compound of formula (Z): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and at least one pharmaceutically acceptable carrier or diluent, and to the use of a compound of formula (J), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a disease, disorder, or condition mediated by Aurora kinase, and methods related thereto.

  本发明涉及一种化合物，其化学式为(Z)：或其结晶形式，或其溶剂化合物；一种固体药物组合物，包括化学式(I)的药效量化合物，或其结晶形式，或其溶剂化合物，以及至少一种药用可接受的载体或稀释剂；以及使用化学式(J)的化合物，或其结晶形式，或其溶剂化合物，治疗患有或受到Aurora激酶介导的疾病、紊乱或症状的患者，以及相关方法。
• Compounds for inhibiting mitotic progression
  申请人：Claiborne Christopher F.

  公开号：US20080167292A1

  公开（公告）日：2008-07-10

  The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  本发明涉及用于癌症治疗的化合物和方法。具体而言，本发明提供了Aurora A激酶的有效抑制剂，包括该化合物的制药组合物以及使用该化合物治疗癌症的方法。
• AURORA KINASE INHIBITORS FOR INHIBITING MITOTIC PROGRESSION
  申请人：Claiborne Christopher F.

  公开号：US20110312942A1

  公开（公告）日：2011-12-22

  The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  本发明涉及用于治疗癌症的化合物和方法。具体而言，本发明提供了强效的Aurora A激酶抑制剂、包含该化合物的制药组合物以及使用该化合物治疗癌症的方法。
• CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE
  申请人：Armitage Ian

  公开号：US20110245234A1

  公开（公告）日：2011-10-06

  The present invention is directed to a compound of formula (I): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and at least one pharmaceutically acceptable carrier or diluent, and to the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a disease, disorder, or condition mediated by Aurora kinase, and methods related thereto.

  本发明涉及一种式（I）的化合物：或其晶体形式，或其溶剂化物；以及包含化合物式（I）或其晶体形式或其溶剂化物的药物有效量和至少一个药物可接受的载体或稀释剂的固体制剂，以及使用化合物式（I）或其晶体形式或其溶剂化物治疗患有或受到由极光激酶介导的疾病、紊乱或病况的患者及相关方法。
• Aurora Kinase Inhibitors for Inhibiting Mitotic Progression
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20150166545A1

  公开（公告）日：2015-06-18

  The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  本发明涉及用于癌症治疗的化合物和方法。特别地，本发明提供了Aurora A激酶的有效抑制剂、包含该化合物的制药组合物以及使用该化合物治疗癌症的方法。